Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 11/20 | 0.63 |
| ▸ | CDK2 | P24941 | 9/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.63 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.63 |
| ▸ | CLK2 | P49760 | 1/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.63 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.63 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23961642 | 0.90 | TDP1 (0.55) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL22651961 | 0.85 | NPSR1 (0.70) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL19112178 | 0.82 | NPSR1 (0.67) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL15387124 | 0.82 | NPSR1 (0.67) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL30356263 | 0.82 | NPSR1 (0.67) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL19112192 | 0.82 | NPSR1 (0.67) | CDK1CDK2CDK5CSNK1DCLK2 | |
| Hydrochloric Acid SCHEMBL30268945 | 0.82 | NPSR1 (0.66) | CDK1CDK2CDK5CSNK1DCLK2 | |
| Hydrochloric Acid SCHEMBL23927317 | 0.82 | NPSR1 (0.66) | CDK1CDK2CDK5CSNK1DCLK2 | |
| Hydrochloric Acid SCHEMBL23927315 | 0.82 | NPSR1 (0.66) | CDK1CDK2CDK5CSNK1DCLK2 | |
| SCHEMBL23927311 | 0.80 | NPSR1 (0.54) | CDK1CDK2CDK5CSNK1DCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2022-10-18 | — | — | US | disclosed |
| EP-3901154-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2020-11-12 | — | — | US | disclosed |
| EP-2664619-B1 | Purine derivatives as tools for screening anti-Alzheimer compounds | MANROS THERAPEUTICS (FR) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | ADORA1, OXGR1, ADORA2A | CDK1 981/4885CDK2 1842/4885CDK5 1097/4885 |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | TPMT, ADORA2A, PNP | CDK1 2687/4885CDK2 3765/4885CDK5 1217/4885 |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | TPMT, ADORA2A, PNP | CDK1 2687/4885CDK2 3765/4885CDK5 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.